As required by section 205, FDA considered regulatory alternatives to the requirements of the rule but determined that the provisions of the final rule constituted the most cost-effective and least burdensome alternative that would meet the objective of the rule.
Although the FDA considered some alternatives, but the final rule was the least burdensome.